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Abstract
Objectives—To evaluate the reliability and cluster structure of the Pediatric Quality of Life 
Inventory Type 1 Diabetes Module 3.0 (PedsQL-T1DM) and associated subscales and to explore 
the associations between PedsQL-T1DM total score and demographic and clinical characteristics 
and clinical indicators among a large racially/ethnically diverse cohort of youth with type 1 
diabetes.
Study design—Principal components analysis was conducted on responses from the PedsQL-
T1DM child self-report forms completed by SEARCH for Diabetes in Youth study participants 
aged ≥5 years. Multivariate linear regression models were fit to examine the associations among 
PedsQL-T1DM total score, demographic and clinical characteristics, and clinical indicators.
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Results—The sample comprised 2602 youth with a mean age of 13.6 ± 4.1 years and a mean 
T1DM duration of 62.1 ± 47.0 months. Principal components analysis did not support the 5 
existing PedsQL-T1DM subscales. In multivariate analyses, the PedsQL-T1DM total score was 
negatively and significantly associated with younger age (5–7 years), female sex, receiving insulin 
by injection (vs pump), having parents without a college degree, Medic-aid/Medicare insurance, 
and having a comorbid medical condition. Youth with poor glycemic control based on their age-
specific hemoglobin A1c target values and those with depressive symptoms had significantly 
lower PedsQL-T1DM scores than their counterparts with good control and no or limited 
depressive symptoms.
Conclusion—This study has identified sociodemographic and clinical characteristics of youth 
with T1DM more likely to experience poor diabetes-specific quality of life. The association of 
lower PedsQL-T1DM scores with depressive symptoms and poor glycemic control is especially 
concerning and may be the focus of future interventions and studies.
Children and adolescents with type 1 diabetes mellitus (T1DM) face many challenges, 
including the usual stressors encountered during these developmental periods, as well as the 
additional physical and emotional stressors associated with having and managing their 
diabetes.1,2 Health-related quality of life (HRQOL) is a measure of the extent to which a 
medical condition influences the physical and psychosocial well being of an individual.2 A 
major goal of diabetes care for youth and their families is good daily diabetes management 
without a reduction in HRQOL. HRQOL also serves as an outcome measure in clinical trials 
of diabetes treatments and interventions.3–5 Previous reports indicate that youth with T1DM 
have a lower general quality of life compared with youth without diabetes.6 The SEARCH 
Study has reported that being on Medicaid, receiving insulin injections (vs using an insulin 
pump), having poor glycemic control (>9%), and having medical comorbidities were all 
independently associated with lower general HRQOL in youth with T1DM.7
Diabetes-specific HRQOL provides a snapshot of an individual’s perception of T1DM 
symptoms and treatment, as well as worries and communication issues specific to having 
T1DM. One diabetes-specific measure of HRQOL, the Pediatric Quality of Life Inventory 
Type 1 Diabetes Module 3.0 (PedsQL-T1DM),6 was developed based on 237 youth with 
T1DM and includes a total score and 5 subscale scores. The Cronbach α coefficient and 
construct validity were reported for the total score and subscale scores in the original study, 
but the statistical analyses possibly used to verify the sub-scales were not reported.6 The 
present study had 3 objectives: (1) to evaluate the reliability and cluster structure of the 
PedsQL-T1DM total and subscale scores; (2) identify demographic and clinical 
characteristics associated with diabetes-specific HRQOL; and (3) explore the associations 
between diabetes-specific HRQOL and selected clinical indicators, including depressive 
symptoms, glycemic control, episodes of diabetic ketoacidosis (DKA), hypoglycemia, 
hospitalizations, and emergency department (ED) visits, among a large, racially/ethnically 
diverse cohort of youth with T1DM.
Methods
SEARCH is a multicenter study that in 2001 began conducting population-based 
ascertainment of youth diagnosed with T1DM at age <20 years.8 SEARCH recruited youth 
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from 4 geographically defined populations, Indian Health Service beneficiaries from 4 
American Indian populations, and enrollees in several managed health care plans. 
Institutional review board(s) for each site approved the study protocol. All registered cases 
were asked to complete a brief initial survey; survey respondents were invited to a research 
visit. During this visit, informed consent and assent (when the individual with T1DM was 
aged <18 years) was obtained, questionnaires were administered, and physical 
measurements and fasting blood samples were obtained from metabolically stable 
participants (ie, no episodes of DKA during the previous month) after a minimum fast of 8 
hours overnight.
All youth aged ≥5 years at the study visit were invited to complete the PedsQL-T1DM.6 The 
PedsQL-T1DM is a 27-item multidimensional instrument developed to assess HRQOL 
specifically related to diabetes for use in children with T1DM. Age-specific child self-report 
forms for age groups 5–7, 8–12, 13–18, and ≥19 years were either read to the child or given 
to the child to read, depending on his or her reading skills. A total score and 5 subscale 
scores (diabetes symptoms, treatment barriers, treatment adherence, worry, and 
communication) can be calculated. Scores range from 0 to 100; higher scores indicate better 
HRQOL.
Age is based on age at the study visit and categorized based on the age-specific PedsQL-
T1DM forms. Race/ethnicity is self-reported, using the standard census questions and 
categorized as Hispanic if of Hispanic ethnicity, by race if non-Hispanic, and as other/
unknown race/ethnicity if multiple races or no race/ethnicity is reported. Highest level of 
parental education was based on the parent with the most education. Health insurance was 
categorized as private insurance, state/federally funded, other (including Indian Health 
Service, student health clinics, military, or other/unknown sources), or none.
Type of diabetes was based on the physician’s clinical diagnosis. Medical comorbid 
conditions included asthma, kidney disease, celiac disease, hypertension, and polycystic 
ovarian syndrome based on self or parental report. Body mass index (BMI) was calculated 
using height/weight measurements obtained at the study visit. Age- and sex-specific 
percentiles for BMI z-scores were assessed using Centers for Disease Control and 
Prevention algorithms based on their 2000 growth charts.9,10 Youth with a BMI z-score 
≥95th percentile were categorized as obese, those with BMI z-score in the 85th to <95th 
percentile as overweight, those with BMI z-score >15th to <85th percentile as healthy 
weight, and those with BMI z-score <15th percentile as underweight.11 Diabetes treatment 
was categorized as insulin injections <3 times/day, injections ≥3 times/day, or use of an 
insulin pump.
Glycemic control was based on glycated hemoglobin (HbA1c) measured in whole blood 
with an automated nonporous ion-exchange high-performance liquid chromatography 
system (model G-7; Tosoh Bioscience, Montgomeryville, Pennsylvania). To examine the 
association between diabetes-specific HRQOL and glycemic control, HbA1c values were 
categorized using the American Diabetes Association–recommended age-specific cutpoints 
for good control (<8.5% for age <6 years, <8.0% for age 6–12 years, <7.5% for age 13–18 
years, and <7.0% for age ≥19 years).12 Poor control was defined as >9.5% regardless of age, 
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based on the Diabetes Control and Complications Trial adolescent control group 
documenting risk for complications,13 and intermediate control was defined as an HbA1c 
between those 2 values. Participants or their parents/guardians reported acute health care 
utilization (number of hospitalizations and ED visits for any reason) and acute complications 
(number of severe hypoglycemia and DKA episodes in the previous 6 months). To ensure 
that HbA1c was reflective of a period after the initial treatment regimen was established, and 
that hospitalizations and ED visits did not include those around the time of diagnosis, the 
sample was restricted to youth with diabetes of at least 1 year’s duration. The presence of 
depressive symptoms was assessed for youth aged ≥10 years using the Center for 
Epidemiologic Studies Depression (CES-D) scale.14 CES-D scores can range from 0 to 60 
and are categorized as 0–15, none/minimal depressive symptoms; 16–23, mild depressive 
symptoms; or 24–60, moderate/severe depressive symptoms.15–17
Of the 4203 youths aged ≥5 years who completed a study visit from the prevalent 2001 and 
incident 2002–2005 cohorts, 1601 youth were excluded (for not having T1DM, not taking 
insulin, not having HbA1c measurements, or having diabetes duration <12 months), 
resulting in a sample of 2602 youth. The analysis of PedsQL-T1DM and depressive 
symptoms was limited to youth aged ≥10 years (n = 2027), because only these youth 
completed the CES-D scale.
Statistical Analyses
Cronbach’s α was used to assess the internal consistency and reliability of total and subscale 
scores, as described by Varni et al.6 Principal components analysis (PCA) using the SAS 
VARCLUS procedure (SAS Institute, Cary, North Carolina) was used to separate PedsQL-
T1DM items into disjoint clusters.18 The algorithm was constrained to produce only 5 
clusters to determine whether they corresponded with the 5 originally published subscales6 
and then repeated to determine the actual number of clusters required to explain 60% and 
80% of the total variance. Squared correlations between each variable and its assigned 
cluster (R2O), as well as between each variable and its next nearest cluster (R2N), were 
computed. The ratio (1–R2O)/(1–R2N) is reported as a measure of cluster fit, where smaller 
values of this ratio indicate well-separated clusters.
ANOVA F-tests were used to test for unadjusted differences in mean total score by 
categorical demographic characteristics, clinical characteristics, and clinical indicators. 
Pearson correlation coefficients were calculated for the PedsQL-T1DM total score and 
HbA1c and CES-D scores. A multivariate linear regression model was fit to examine the 
independent associations between demographic and clinical characteristics and the PedsQL-
T1DM total score. Then separate multiple linear regression models were fit for each clinical 
indicator to determine an associate with PedsQL-T1DM total score, after adjustment for 
demographic and clinical characteristics. Although no minimum clinically important 
difference (MCID) has been reported for the PedsQL-T1DM 3.0,6 the differences for the 
Pediatric Quality of Life Inventory 4.0 Generic Core Scales is 4.5 points,19 so we considered 
this the reference value. All analyses were performed with SAS version 9.2 (SAS Institute).
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The study sample comprised 2602 youth (mean age, 13.6 ± 4.1 years) who had T1DM for a 
mean duration of 62.1 ± 47.0 months and had a mean HbA1c value of 8.5% ± 1.6%. Three-
quarters were non-Hispanic white, 50% were male, and ≈80% had a parent with at least 
some college education and were privately insured. Approximately half of the youth in the 
cohort used multiple daily insulin injections, and 22% used an insulin pump.
PedsQL-T1DM Scale Reliability and PCA
The Cronbach α coefficient for the PedsQL-T1DM total score was ≥0.80 for all age groups 
(Table I), exceeding the threshold of 0.70 for scale reliability.20 Individual subscale score 
coefficients were more variable. The orthoblique PCA assuming 5 clusters explained only 
42.7% of the total variation in PedsQL-T1DM item responses, and the items did not load on 
the predesignated subscales (Table II; available at www.jpeds.com). Eleven clusters were 
required to explain at least 60% of the variance, and 18 clusters were required to explain at 
least 80% of the variance (data not shown). Given these findings, we conducted the 
remainder of the analyses using just the PedsQL-T1DM total score.
Demographic and Clinical Characteristics and PedsQL-T1DM
We observed significant variability in the PedsQL-T1DM total score by participants’ 
demographic and clinical characteristics (Table III). The PedsQL-T1DM total score was 
significantly associated with all demographic characteristics and with all clinical 
characteristics except diabetes duration. Because a statistical interaction was reported for sex 
and age category for the PedsQL generic scores,7 we examined mean total scores by age 
category and sex and found minimal sex differences for 5- to 7-year olds and 8- to 12-year-
olds (data not shown), with lower scores for adolescent (aged 13–18 years) females 
compared with males (females, 72.2 ± 13.2 years; males, 76.1 ± 11.9 years; P < .001) and 
young adults (≥19 years; females, 67.3 ± 14.0 years; males, 73.2 ± 12.8 years; P < .001).
Most demographic and clinical characteristics remained associated with PedsQL-T1DM 
total score in the multivariate model. Females aged 5–7 years whose parents had less than a 
college degree and who had Medicaid/Medicare insurance had the lowest PedsQL-T1DM 
scores. In addition, youth who took insulin by injection (vs a pump), and those with a 
medical comorbidity had lower PedsQL-T1DM total scores. The statistical interaction 
between age and sex persisted after adjustment for other demographic and clinical variables 
in the multivariate analysis (data not show), but had minimal impact on the other covariates 
in the model. Age was the sole variable to demonstrate both a statistically significant 
difference and an MCID for the PedsQL-T1DM total score.
Clinical Indicators and PedsQL-T1DM
Both HbA1c and CES-D scores were modestly correlated with PedsQL-T1DM total score (r 
= −0.232 and −0.568, respectively; P < .0001 for both). The magnitude of the correlation 
between HbA1c and PedsQL-T1DM total score varied by age category: 5–7 years, r = 
−0.096; 8–12 years, r = −0.198; 13–18 years, r = −0.303; ≥19 years, r = −0.230. The 
PedsQL-T1DM total score was associated with all clinical indicators in the unadjusted and 
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multivariate models (Table IV). The strongest association was observed between PedsQL-
T1DM total score and depressive symptoms. Compared with youth with minimal or no 
depressive symptoms, youth with mild depressive symptoms had a 10.8-point lower average 
total score, and those with moderate/severe depressive symptoms had a 19.2-point lower 
average total score (P < .0001 for both). Compared with youth with good glycemic control, 
youth with intermediate control had 3.2-point lower average total score, and those with poor 
control had a 7.0-point lower average total score (P < .0001 for both). Episodes of 
hypoglycemia and DKA demonstrated similar patterns, but the magnitudes of the 
differences were much less pronounced than those for depression or glycemic control.
Discussion
We found that the 5 original subscales of the PedsQL-T1DM module were not supported by 
our PCA. A 5-cluster solution explained only ~43% of the total variation among item 
responses. Our conclusions are consistent with those of Nansel et al,21 who conducted a 
similar analysis on responses from 447 youth with T1DM using PCA with a promax rotation 
and concluded that the PedsQL-T1DM total score, but not the original subscales, was the 
most appropriate unit for analysis. Their 5-factor structure differed from our 5-cluster 
solution, perhaps because of differences in analytic approaches or study populations. Varni 
et al6 used focus groups, cognitive interviews, and field testing to develop this module, but 
to the best of our knowledge did not conduct PCA or any other similar analyses to confirm 
the statistical properties of their subscales.
Our study found significant independent associations between PedsQL-T1DM total score 
and demographic and clinical characteristics in a large, diverse cohort of youth with T1DM. 
The largest differences by demographic characteristics were those observed by age group, 
with the youngest children having the lowest total scores. There are only 3 response options 
for children aged 5–7 years, compared with 5 for children aged 8 years and older, a 
difference that might have contributed to some of the differences in scores by age. Females 
also tended to have lower HRQOL than males, with sex differences emerging in the teenage 
years, a finding consistent with that reported by Hoey et al from the multinational Hvidøre 
Study.22 The differences in PedsQL-T1DM mean total score by race/ethnicity were not 
statistically significant after adjustment for other characteristics, likely due in part to the 
relatively small number of Native American youth included in the study (n = 18).
No significant differences in HRQOL by BMI category were seen after adjusting for other 
demographic and clinical characteristics for either diabetes-specific HRQOL or generic 
HRQOL, as reported previously.7 In contrast, the Hvidøre Study Group reported that greater 
BMI was associated with poorer diabetes-specific HRQOL in more than 2000 adolescents 
with T1DM assessed using the Diabetes Quality of Life Questionnaire.22,23 Schwimmer et 
al24 found that severely-obese youth (mean BMI, 34.7) had much lower HRQOL scores 
compared with healthy-weight children, having scores similar to children with cancer, and 
Williams et al25 reported smaller but significant differences in HRQOL across weight 
groups in a community sample. Our findings may suggest that in this US-based cohort, 
being overweight or obese in addition to having T1DM is not associated with the same 
reduction in HRQOL seen in otherwise healthy children. We also observed minimal 
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differences in HRQOL for children with comorbid medical conditions, suggesting that the 
PedsQL-T1DM is less sensitive to differences in HRQOL not related to diabetes.
Among the clinical indicators, the strongest association was with depressive symptoms in 
youth aged ≥10 years. The PedsQL-T1DM total score was 20 points lower in youth with 
moderate/severe depressive symptoms compared with youth with no or minimal symptoms. 
Given that both HRQOL and depression are psychological constructs, this finding is not 
unexpected. The negative correlation between the CES-D and the PedsQL-T1DM scores 
was moderately high (r = −0.57) and consistent with that reported by Nansel et al (r = 
−0.54).21
We found a dose-response relationship between glycemic control and PedsQL-T1DM score, 
with the highest scores in youth with good control. HbA1c and the PedsQL-T1DM total 
score were modestly negatively correlated (r = −0.232), slightly less so than reported by 
Ingerski et al (r = −0.28),26 but more so than reported by Nansel et al (r = −0.08 and 
−0.09).21 Varni et al6 found no significant correlation. The Hvidøre Study found an 
association between lower mean HbA1c value and better HRQOL,22 and Hassan et al27 also 
reported an inverse association between PedsQL-T1DM total score and HbA1c. It is 
possible that persons with higher HRQOL, which we found to be associated with markers of 
better socioeconomic status (ie, having private insurance, higher parental education, being 
on an insulin pump), might have more resources to aid in achieving good control, but we 
cannot infer a causal association from cross-sectional data.
Given our large sample, the issue of statistical versus clinical significance should be 
addressed. In most cases, statistical differences in demographic data and clinical 
characteristics did not achieve the MCID for the total score that was recommended for the 
PedsQL generic scale except as previously noted for age, whereas the differences for 
depression and glycemic control categories exceeded these thresholds.
Although other measures of psychological distress might be associated with HRQOL, these 
measures are not included in the SEARCH study protocol. Similarly, we did not evaluate 
issues related to family relationships, which also might be associated with HRQOL in youth 
with T1DM.28 The cross-sectional nature of these data precluded us from examining the 
direction of associations between variables of interest, such as whether lower HRQOL 
drives poorer glycemic control and elevated depressive symptomatology, or vice versa. In 
addition, we were unable to assess temporal trends, such as whether HRQOL increases from 
childhood to adolescence and then declines in later adolescence. Despite extensive efforts to 
optimize recruitment, older youth were less likely to participate in the study visit than those 
diagnosed at younger ages.29 The majority of youth in these analyses were insured privately 
or through government-funded programs. Even though these results might not be 
generalizable to uninsured youth, the majority of youth with T1DM will be eligible for 
insurance under subsidized programs if they cannot afford private insurance.
Major strengths of the present study include the use of a validated measure of diabetes-
specific HRQOL, as well as extensive clinical and demographic measures in a large diverse 
cohort of more than 2500 US youth with T1DM. The smaller number of Asian, Pacific 
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Islander, and Native American youth in this analysis is consistent with the lower prevalence 
of T1DM in these groups compared with other racial/ethnic groups.30
The findings of this study highlight demographic and clinical characteristics of youth with 
T1DM who are more likely to experience poor diabetes-specific HRQOL. Our data also 
suggest that in the presence of lower diabetes-specific HRQOL, a number of indicators of 
poor clinical functioning also may be affected, most importantly increased depressive 
symptoms and poor glycemic control. These findings are important for clinicians and 
researchers alike who are providing clinical care or conducting studies of demographically 
diverse youth with T1DM. In the clinical setting, poor glycemic control can be readily 
identified using laboratory test results, but depressive symptoms and poor or worsening 
diabetes-specific HRQOL might not be. Our findings suggest that in the presence of poor 
glycemic control, screening for depressive symptoms or poor diabetes-specific HRQOL may 
be warranted. In addition, clinic-based strategies aimed at preventing the development 
and/or worsening of diabetes-specific HRQOL also may benefit from the inclusion of 
strategies for reducing depressive symptoms. Future research studies should investigate 
whether these interventions may ultimately promote better disease management, 
subsequently improving glycemic control for this pediatric population.
Acknowledgments
Funding information is available at www.jpeds.com (Appendix 2). The findings and conclusions in this report are 
those of the authors and do not necessarily represent the official position of the Centers for Disease Control and 
Prevention.
The SEARCH for Diabetes in Youth Study is indebted to the many youth and their families and health care 
providers, whose participation made this study possible.
Glossary
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HRQOL Health-related quality of life
MCID Minimum clinically important difference
PCA Principal components analysis
PedsQL-T1DM Pediatric Quality of Life Inventory Type 1 Diabetes Mellitus
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